Fluorescent Glyconanoparticle Production Service
Overview
Fluorescent glyconanoparticles combine fluorescent properties with the specific recognition of glycan molecules, making them highly specific and sensitive, and showing great potential for biomedical, chemical sensing, and materials science applications. Their fluorescent properties allow for effective detection and imaging at the microscopic level, while the presence of sugar molecules gives them the ability to recognize specific biomolecules or cells.
Unveiling the Secret of Fluorescent Glyconanoparticle Production
Glyconanotechnology utilizes the unique properties of nanomaterials to study and manipulate the structure and function of saccharides. CD BioGlyco has advanced GlycoNano™ Platform and has extensive research experience in the field of glyconanomics. We offer a wide range of Glyconanoparticle Production Services to our clients, in which we produce nanoparticles including but not limited to Carbohydrate-based Nanoparticle, Gold Glyconanoparticle, Silver Glyconanoparticle, Magnetic Glyconanoparticle, Quantum Dot (QD), and fluorescent glyconanoparticle.
Workflow
Synthesis of Functionalized QDs
First, we synthesize water-soluble CdS QDs using mercaptopropionic acid (MPA) as a stabilizer. The MPA-capped CdS QD solution is mixed with EDC and 3-aminophenylboronic acid (APBA) for the conjugation reaction. After shaking the reaction for 3 h at room temperature away from light, unbound APBA is removed using ultrafiltration to obtain APBA-functionalized QDs (APBA QDs). APBA is covalently bound to the CdS QDs during the synthesis process, and the successful synthesis of the functionalized QDs provided the necessary recognition capability for the subsequent synthesis of glyconanoparticles, enabling the sugar nanoparticles to enhance the signal by binding to the functionalized QDs.
Synthesis of Fluorescent Markers
APBA and FITC are reacted under light-free conditions for 24h to obtain APBA-functionalized FITC. After the reaction, purification by silica gel column chromatography is performed to obtain APBA FITC.
Synthesis of Fluorescent Glyconanoparticles
We prepare PSA gold nanoparticles (AuNPs) by reducing HAuCl4 with the help of citric acid and stabilizing it with polyvinyl alcohol (PSA). HAuCl4 and PSA are mixed and heated, followed by the addition of citric acid and stirring to obtain a clear red glyconanoparticle solution. After adding APBA QDs to the PSA AuNPs solution, a change in the color of the solution (from red to purple) is observed, which indicates that the APBA QDs have undergone a cross-linking reaction with the PSA AuNPs through their PBA groups to form aggregates.
Blocking Non-specific Adsorption
In our experiments, we use 1% bovine serum albumin (BSA) as a sealing agent, which can effectively block non-specific adsorption. After cell culture, the microtiter plate is first closed with BSA, which can reduce the non-specific binding between the probe and the surface of the microtiter plate, thus improving the specificity of the assay.

Applications
- In drug development, it can be used as a drug carrier for targeted delivery, improving therapeutic efficacy and reducing side effects.
- It can be effectively used to build chemical sensors with high sensitivity, capable of detecting trace amounts of substances present in the environment with extreme precision.
- In the biomedical field, it can be used for cell imaging and tracking to help study the physiological and pathological processes of cells.
Advantages
- We precisely modulate the size, shape, and chemical composition of the nanoparticles to optimize their fluorescence properties and the binding efficiency of the sugar molecules.
- Our manufacturing technology enables large-scale production and meets the needs from laboratory research to real-world applications.
- In the production process, conditions are carefully optimized so that the nanoparticles maintain a stable structure and excellent performance under a wide range of environmental conditions.
Publication Data
Technologies: Magnetic resonance imaging (MRI), Near infrared fluorescence imaging (NIRF)
Journal: Nanomaterials
Published: 2024
IF: 4.55
Results: The main research of this article is the development of a dual-modality MRI/fluorescence nanoparticle imaging contrast agent for prostate cancer, specifically USPIO(Cy7.5)-BBN nanoparticles. The study investigated the surface coating and functionalization of ultrasmall iron oxide nanoparticles, as well as the biocoupling of USPIO(Cy7.5)-BBN. The results showed that the nanoparticles were highly specific for GRPr-expressing PC-3 cells, demonstrating their potential in prostate cancer targeting imaging. In in vivo studies, using a mouse model of prostate tumors, USPIO(Cy7.5)-BBN significantly enhanced the contrast between prostate cancer and surrounding tissues, demonstrating its ability to efficiently perform multimodal imaging through specific binding to GRP receptors. The excellent multimodal imaging capability of this nanoparticle platform bodes well for its application in clinical prostate cancer diagnosis and image-guided therapy.
Fig.1 Diagrammatic representation of the interaction between USPIO(Cy7.5)-BBN and prostate cancer cells. (Xu, et al., 2024)
Frequently Asked Questions
- How about the biocompatible of fluorescent glyconanoparticles?
They tend to exhibit better biocompatibility if the core material chosen has low toxicity and the surface is suitably modified, e.g., covered with a hydrophilic polymer or a biocompatible molecule. With our rational design and optimization, fluorescent sugar nanoparticles can achieve good biocompatibility, thus providing the possibility of their application in biomedical fields. -
How is the stability of fluorescent glyconanoparticles in vivo?
Smaller-sized particles may be more readily cleared by the kidneys, whereas larger-sized particles may remain in the body for longer periods, but may also face more phagocytosis by macrophages. Suitable surface coatings can enhance stability by reducing non-specific interactions with biomolecules in vivo and decreasing the probability of recognition and clearance by the immune system. With careful design and optimization, such as selecting appropriate materials, precisely controlling the particle size, and optimizing the surface modification, Fluorescent glyconanoparticles can maintain a certain degree of stability in vivo to achieve their intended functions, such as prolonged imaging, drug delivery, and so on.
CD BioGlyco is committed to offering first-class fluorescent glyconanoparticle production services. We possess a group of highly proficient experts and cutting-edge facilities to guarantee the efficient and accurate synthesis of fluorescent glyconanoparticles. If you need any assistance regarding our services, please feel free to contact us!
Reference
- Xu, H; et al. Bimodal MRI/fluorescence nanoparticle imaging contrast agent targeting prostate cancer. Nanomaterials. 2024, 14(14): 1177.
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





